Sibtain Haider

Mr. Sibtain Haider

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Trends in Biotechnology
Verified
Journal Article
Closed access
MKMuhammad Zuhaib Khan
Muhammad Zuhaib Khan
SHSibtain Haider
Sibtain Haider
SMShahid Mansoor
Shahid Mansoor
IAImran Amin
Imran Amin

Verified
Journal Article
Open access
PDF file
SHSibtain Haider
Sibtain Haider
CMClaudio Mussolino
Claudio Mussolino
CRISPR–Cas9 is a powerful genome-editing technology that can precisely target and cleave DNA to induce double-strand breaks (DSBs) at almost any genomic locus. While this versatility holds tremendous therapeutic potential, the predominant cellular pathway for DSB repair—non-homologous end-joining (NHEJ)—often introduces small insertions or deletions that disrupt the target site. In contrast, homology-directed repair (HDR) utilizes exogenous donor templates to enable precise gene modifications, including targeted insertions, deletions, and substitutions. However, HDR remains relatively inefficient compared to NHEJ, especially in postmitotic cells where cell cycle constraints further limit HDR. To address this challenge, numerous methodologies have been explored, ranging from inhibiting key NHEJ factors and optimizing donor templates to synchronizing cells in HDR-permissive phases and engineering HDR-enhancing fusion proteins. These strategies collectively aim to boost HDR efficiency and expand the clinical and research utility of CRISPR–Cas9. In this review, we discuss recent advances in manipulating the balance between NHEJ and HDR, examine the trade-offs and practical considerations of these approaches, and highlight promising directions for achieving high-fidelity genome editing in diverse cell types.

18 April 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ACAntonio Carusillo
Antonio Carusillo
SHSibtain Haider
Sibtain Haider
RSRaul Schäfer
Raul Schäfer
MRManuel Rhiel
Manuel Rhiel
DTDaniel Türk
Daniel Türk
CMClaudio Mussolino
Claudio Mussolino
Precise genome editing requires the resolution of nuclease-induced DNA double strand breaks (DSBs) via the homology-directed repair (HDR) pathway. In mammals, this is typically outcompeted by non-homologous end-joining (NHEJ) that can generate potentially genotoxic insertion/deletion mutations at DSB sites. Because of higher efficacy, clinical genome editing has been restricted to imperfect but efficient NHEJ-based approaches. Hence, strategies that promote DSB resolution via HDR are essential to facilitate clinical transition of HDR-based editing strategies and increase safety. Here we describe a novel platform that consists of a Cas9 fused to DNA repair factors to synergistically inhibit NHEJ and favor HDR for precise repairing of Cas-induced DSBs. Compared to canonical CRISPR/Cas9, the increase in error-free editing ranges from 1.5-fold to 7-fold in multiple cell lines and in primary human cells. This novel CRISPR/Cas9 platform accepts clinically relevant repair templates, such as oligodeoxynucleotides (ODNs) and adeno-associated virus (AAV)-based vectors, and has a lower propensity to induce chromosomal translocations as compared to benchmark CRISPR/Cas9. The observed reduced mutational burden, resulting from diminished indel formation at on- and off-target sites, provides a remarkable gain in safety and advocates this novel CRISPR system as an attractive tool for therapeutic applications depending on precision genome editing.

1 May 2021 in Journal of Materials Research and Technology
Verified
Journal Article
Open access
ARAmna Rafiq
Amna Rafiq
ATAyesha Taj
Ayesha Taj
SHSibtain Haider
Sibtain Haider
MTMuhammad Ali Tahir
Muhammad Ali Tahir
RZRabisa Zia
Rabisa Zia
IAImran Amin
Imran Amin

7 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SHSibtain Haider
Sibtain Haider
AFAli Faiq
Ali Faiq
MKMuhammad Zuhaib Khan
Muhammad Zuhaib Khan
SMShahid Mansoor
Shahid Mansoor
IAImran Amin
Imran Amin
CRISPR/Cas system has emerged as the most efficient genome editing technology for both eukaryotic and prokaryotic cells. Recently, biologist have started using CRISPR/Cas9 as a defence machinery in plants against DNA viruses by targeting conserve regions of their genome. Considerable resistance requires formation of stable transgenic lines with multiple gRNAs, targeting specific viruses. Development of such transgenic plants is not only time consuming but also there will always be some uncertainty of their efficiency and off targets in plant genome. Newly discovered miniature CRISPR/Cas12f (Cas14a) system has unique ability to chop down every ssDNA fragment once activated through targeted cleavage. Here we report first fully functional transient CRISPR/Cas12f system in plants. We also show that Cas12f with just one gRNA is enough for substantial broad-spectrum resistance against Gemini viruses. Plant phenotype showed nearly complete recovery and qPCR results showed multifold decrease infection of CLCuV in CRISPR/Cas12f treated plants compare to the infected plants (infected with CLCuMuV and CLCuKV). Smaller size, broad range and more efficiency make Cas12f a superior alternative of Cas9 against diverse group of ssDNA viruses.